Technology | October 09, 2008

FDA Approves Boston Scientific's Second-Generation TAXUS Liberte DES


October 10, 2008 - Boston Scientific Corp. today said it received FDA approval to market its second-generation TAXUS Liberte Paclitaxel-Eluting Coronary Stent System and the company plans to launch the stent early next month in the U.S.

The introduction will take place following completion of the introduction of its TAXUS Expresss2 Atom Paclitaxel-Eluting Coronary Stent System, which was approved by the FDA last month. The TAXUS Liberte stent was launched in Europe and other international markets in 2005.

The company said the new stent has substantially thinner struts and a more flexible cell geometry for improved deliverability, as well as uniform strut distribution designed specifically for drug elution.

The TAXUS stent systems - both Liberte and Express2 - have been evaluated by the industry’s most extensive randomized, controlled clinical trial program, with follow-up to five years in some cases. These trial results have been supplemented by data on more than 35,000 patients enrolled in post-approval registries. To date, about 4.6 million TAXUS stents have been implanted globally, making them the world’s most frequently used drug-eluting stents, the company said.

The TAXUS Express2 stent (not the newer TAXUS Liberte stent) was used as the control against Abbott’s Xience V Everolimus-Eluting Coronary Stent System in the SPIRIT II and III trials.

The TAXUS Liberte Stent is not available for sale in Japan, where it is undergoing regulatory review.

For more information: www.bostonscientific.com


Related Content

News | Stents Drug Eluting

October 31, 2023 — SMT (Sahajanand Medical Technologies), a leading medical device company in India, focused on ...

Home October 31, 2023
Home
News | Stents Drug Eluting

October 10, 2023 — Elixir Medical, a developer of innovative cardiovascular technologies, announced it will present ...

Home October 10, 2023
Home
News | Stents Drug Eluting

July 13, 2023 — Elixir Medical, a developer of breakthrough cardiovascular technologies, announced enrollment completion ...

Home July 13, 2023
Home
News | Stents Drug Eluting

July 12, 2023 — In a late breaking trial session during EuroPCR 2023 in Paris, on behalf of the HOST-IDEA study ...

Home July 12, 2023
Home
News | Stents Drug Eluting

May 25, 2023 — First-generation bioresorbable vascular scaffolds (BVS) may be just as effective as drug-eluting metallic ...

Home May 25, 2023
Home
News | Stents Drug Eluting

January 2, 2023 — The U.S. Food and Drug Administration (FDA) has approved the BioFreedom Drug Coated Coronary Stent ...

Home January 02, 2023
Home
News | Stents Drug Eluting

December 23, 2022 — According to Coherent Market Insights, the global Drug Eluting Stents market is estimated to be ...

Home December 23, 2022
Home
News | Stents Drug Eluting

June 2, 2022 — Elixir Medical, a developer of innovative, drug-eluting cardiovascular devices, announced print ...

Home June 02, 2022
Home
News | Stents Drug Eluting

February 16, 2022 – Elixir Medical, a developer of innovative, drug-eluting cardiovascular devices, has announced ...

Home February 16, 2022
Home
News | Stents Drug Eluting

January 26, 2021 — The U.S. Food and Drug Administration (FDA) has cleared Boston Scientific's Synergy Megatron Drug ...

Home January 26, 2021
Home
Subscribe Now